Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.

Recenti progressi in medicina - 1 Jun 2021

Giuliani Jacopo, Bonetti Andrea

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Carbazoles
Share to Carcinoma, Non-Small-Cell Lung
Share to Cost-Benefit Analysis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Piperidines

Share to Protein Kinase Inhibitors

Source

Identifiers

PMID: 34128941
DOI: 10.1701/3620.36032

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Alectinib in first-line treatment for advanced anaplastic lymphoma kinase mutation-positive (alk+) non-small cell lung cancer (NSCLC): a cost-effective change.PMID 34128941Read ↗

Alectinib for treatment of ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.Semantic proximity Read ↗

Pharmacologic Costs of Tyrosine Kinase Inhibitors in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations: A Review of Pivotal Phase III Randomized Controlled Trials.Semantic proximity Read ↗

Alectinib for advanced ALK-positive non-small-cell lung cancer.Semantic proximity Read ↗

Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases.Semantic proximity Read ↗

Clinical and economic review of erlotinib in non-small-cell lung cancer.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase Mutation-Positive Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer.Semantic proximity Read ↗

Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

LBA55 Mechanisms of acquired resistance to first-line amivantamab plus lazertinib versus osimertinib in patients with EGFR-mutant advanced non-small cell lung cancer: An early analysis from the phase III MARIPOSA studySemantic proximity Read ↗

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read ↗

Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.